RxDoctor Payments Data

Lauren Steinmetz, MD

Family Medicine · Orchard Park, NYNPI 1447670203

Payments from drug & device makers

$2,387in general payments, 2019–2025

Across 134 payments — averaging $17.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$339
  • Lilly USA, LLC$290
  • AstraZeneca$206
  • AbbVie$203
  • Pfizer$186
  • GSK$160
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$2,37399%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,387 in reported general payments places this provider in the 75th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$29,888
Medicare patients
92
Services billed
357

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban34$38,088
OzempicSemaglutide30$36,943
JardianceEmpagliflozin29$36,416
TrulicityDulaglutide25$35,026
MounjaroTirzepatide22$24,763
MyrbetriqMirabegron19$12,979
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$10,884
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl63$6,724
ShingrixVaricella-Zoster Ge/As01b/Pf20$4,534
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$4,242
Albuterol Sulfate HfaAlbuterol Sulfate102$3,412
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$3,263
SynthroidLevothyroxine Sodium30$3,204
Levothyroxine Sodium165$2,959
Pregabalin38$2,811

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$290$59,78947 claims
PfizerEliquis$186$38,08834 claims
Novo NordiskOzempic$339$36,94330 claims
Boehringer IngelheimJardiance$118$36,41629 claims
GSKTrelegy Ellipta, Shingrix$160$15,41833 claims
Astellas Pharma US IncMyrbetriq$49$12,97919 claims
AbbVieSynthroid$203$3,20430 claims
AstraZenecaSymbicort$206$2,62311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,321 family medicine providers in New York.

Other family medicine in Orchard Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →